Cerca
Close this search box.

Bifidobacterium lactis – Bb12

Tabella dei contenuti

Clinical indications

diarrhea

Area of use

Gastroenterology strain | Antibiotic associated diarrhea in children

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1B/5 drops or 1M/gram CFU

FUNCTIONALITY
AAD – Antibiotic associated diarrhea – Prevention [children use]

Scientific support

Human clinical trials

Corrêa, N.B., L.A. Péret Filho, F.J. Penna, F.M.S. Lima, and J.R. Nicoli. “A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus thermophilus for prevention of antibiotic-associated diarrhea in infants.” Journal of clinical gastroenterology 39.5 (2005): 385-389.


Antipathogenic strain I CID – Common infectious disease in children

Characteristics

DAILY DOSAGE IN CLINICAL STUDY
1B/5 drops or 1M/gram CFU

FUNCTIONALITY
CID – Common infectious disease – community acquired [children use]

Scientific support

Human clinical trial

Taipale, T., K. Pienihäkkinen, E. Isolauri, C. Larsen, E. Brockmann, P. Alanen, J. Jokela, and E. Söderling. “Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy.” British Journal of Nutrition 105.3 (2011): 409-416.

Saavedra, J.M., A. Abi-Hanna, N. Moore, and R.H. Yolken. “Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety.” The American journal of clinical nutrition 79.2 (2004): 261-267.

Oppure effettua il login